MedTrace Logo

Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

NCT02724761 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-03-31

No results posted yet for this study

Summary

Our double-blinded, randomized control trial will assess the effect of nebulized racemic epinephrine inpatients undergoing anterior cervical discectomy and fusion (ACDF) procedures. The investigators have had success in managing post-operative dysphagia in patients undergoing ACDF with the administration of this drug. Half of the participants will review nebulized epinephrine. The other half will receive placebo.

Conditions

Interventions

DRUG

Racemic Epinephrine

1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery

DRUG

Placebo (for racemic epinephrine)

0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)

Sponsors & Collaborators

  • More Foundation

    collaborator OTHER

  • Banner Health

    collaborator OTHER

  • Andrew Chung

    lead OTHER

Principal Investigators

  • Norman Chutkan, MD · The CORE Institute, Banner University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-06-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724761 on ClinicalTrials.gov